FLT3-话题@MedSci

#FLT3#

40篇内容 | 1826人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1538888, encodeId=6150153888870, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：靶向PRMT1介导的FLT3甲基化有望打破MLL重排型ALL的持续存在, objectType=article, longId=177372, objectId=36981e7372b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36981e7372b1, replyNumber=0, likeNumber=0, createdTime=2019-08-11, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36981e7372b1, moduleTitle=Blood：靶向PRMT1介导的FLT3甲基化有望打破MLL重排型ALL的持续存在, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36981e7372b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538887, encodeId=773a153888e68, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：环状RNA，circMYBL2，可调节FLT2的表达促进FLT3-ITD AML进展, objectType=article, longId=177312, objectId=9e901e731241, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e901e731241, replyNumber=0, likeNumber=69, createdTime=2019-08-10, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e901e731241, moduleTitle=Blood：环状RNA，circMYBL2，可调节FLT2的表达促进FLT3-ITD AML进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9e901e731241)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538886, encodeId=d8db1538886b1, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：PRMT1介导FLT3甲基化促进FLT3-ITD+AML细胞存活维持, objectType=article, longId=170117, objectId=36621e0117ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36621e0117ad, replyNumber=0, likeNumber=76, createdTime=2019-06-26, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36621e0117ad, moduleTitle=Blood：PRMT1介导FLT3甲基化促进FLT3-ITD+AML细胞存活维持, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36621e0117ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538885, encodeId=a009153888513, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：在急性髓系白血病中，NPM1c如何影响FLT3-D835Y的定位及信号？, objectType=article, longId=168966, objectId=b5f716896682, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5f716896682, replyNumber=0, likeNumber=75, createdTime=2019-06-24, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5f716896682, moduleTitle=Blood：在急性髓系白血病中，NPM1c如何影响FLT3-D835Y的定位及信号？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b5f716896682)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538884, encodeId=c0c7153888439, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=第24届EHA：pan-FLT3 / pan-BTK抑制剂CG-806的临床前数据, objectType=article, longId=168608, objectId=f819168608ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f819168608ec, replyNumber=0, likeNumber=51, createdTime=2019-06-18, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f819168608ec, moduleTitle=第24届EHA：pan-FLT3 / pan-BTK抑制剂CG-806的临床前数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f819168608ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538883, encodeId=4b4115388830b, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Lancet Oncol：采用quizartinib治疗复发性/难治性FLT3-ITD阳性的急性髓系白血病, objectType=article, longId=167799, objectId=90c516e799ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=90c516e799ed, replyNumber=0, likeNumber=63, createdTime=2019-06-08, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=90c516e799ed, moduleTitle=Lancet Oncol：采用quizartinib治疗复发性/难治性FLT3-ITD阳性的急性髓系白血病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=90c516e799ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538882, encodeId=8ec91538882b4, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：FLT3-ITD如何干扰急性早幼粒白血病治疗效果？, objectType=article, longId=159662, objectId=241f15966237, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=241f15966237, replyNumber=0, likeNumber=62, createdTime=2019-02-10, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=241f15966237, moduleTitle=Blood：FLT3-ITD如何干扰急性早幼粒白血病治疗效果？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=241f15966237)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538881, encodeId=d4021538881e9, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=J Med Chem:合肥研究院研发出针对急性髓性白血病FLT3-ITD突变选择性的第三代新型FLT3激酶抑制剂, objectType=article, longId=157734, objectId=5a8f15e7340d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a8f15e7340d, replyNumber=0, likeNumber=81, createdTime=2019-01-11, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a8f15e7340d, moduleTitle=J Med Chem:合肥研究院研发出针对急性髓性白血病FLT3-ITD突变选择性的第三代新型FLT3激酶抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a8f15e7340d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538880, encodeId=25ae1538880d7, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：Midostaurin可明显延长携带FLT3-ITD的急性髓系白血病患者的无进展存活期, objectType=article, longId=157647, objectId=a03815e64713, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a03815e64713, replyNumber=0, likeNumber=63, createdTime=2019-01-10, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a03815e64713, moduleTitle=Blood：Midostaurin可明显延长携带FLT3-ITD的急性髓系白血病患者的无进展存活期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a03815e64713)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538879, encodeId=d7c315388e9e5, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：竺晓凡/程涛教授团队取得重大突破，揭晓FLT3为PRC2突变T-ALL潜在治疗靶点！, objectType=article, longId=151133, objectId=0fe615113338, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fe615113338, replyNumber=0, likeNumber=64, createdTime=2018-10-17, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fe615113338, moduleTitle=Blood：竺晓凡/程涛教授团队取得重大突破，揭晓FLT3为PRC2突变T-ALL潜在治疗靶点！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fe615113338)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538878, encodeId=d62115388e8be, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Lancet Oncol：单药应用时，奎轧替尼能否为FLT3 ITD阳性复发难治AML带来获益？, objectType=article, longId=146672, objectId=d3de1466e2be, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3de1466e2be, replyNumber=0, likeNumber=77, createdTime=2018-08-16, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3de1466e2be, moduleTitle=Lancet Oncol：单药应用时，奎轧替尼能否为FLT3 ITD阳性复发难治AML带来获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3de1466e2be)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538877, encodeId=7d2615388e744, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Stem cells：Fms样酪氨酸激酶3-配体（Flt3-L）可促进CD8α+类浆细胞前体树突状细胞亚群的发展和功能, objectType=article, longId=145701, objectId=a564145e019e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a564145e019e, replyNumber=0, likeNumber=57, createdTime=2018-08-04, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a564145e019e, moduleTitle=Stem cells：Fms样酪氨酸激酶3-配体（Flt3-L）可促进CD8α+类浆细胞前体树突状细胞亚群的发展和功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a564145e019e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538876, encodeId=bc5415388e675, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：Quizartinib单药治疗复发性/难治性FLT3-ITD突变型急性髓系白血病的效果和安全性, objectType=article, longId=140256, objectId=0af5140256d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0af5140256d5, replyNumber=0, likeNumber=70, createdTime=2018-06-09, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0af5140256d5, moduleTitle=Blood：Quizartinib单药治疗复发性/难治性FLT3-ITD突变型急性髓系白血病的效果和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0af5140256d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538875, encodeId=989a15388e533, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Lancet oncol：Quizartinib，FLT3抑制剂，单独用于复发性/难治性急性髓系白血病患者可获得良好疗效, objectType=article, longId=139563, objectId=4056139563b2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4056139563b2, replyNumber=0, likeNumber=53, createdTime=2018-06-02, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4056139563b2, moduleTitle=Lancet oncol：Quizartinib，FLT3抑制剂，单独用于复发性/难治性急性髓系白血病患者可获得良好疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4056139563b2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538874, encodeId=93e715388e442, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：酪氨酸激酶抑制剂诱导的DNA修复缺陷使FLT3(ITD)阳性的白血病细胞对PARP1抑制剂治疗敏感, objectType=article, longId=138866, objectId=681b1388668c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=681b1388668c, replyNumber=0, likeNumber=38, createdTime=2018-05-24, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=681b1388668c, moduleTitle=Blood：酪氨酸激酶抑制剂诱导的DNA修复缺陷使FLT3(ITD)阳性的白血病细胞对PARP1抑制剂治疗敏感, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=681b1388668c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538873, encodeId=10b815388e35e, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：基于RNA的FLT3-ITD检测，可用于儿童急性髓系白血病患者的危险分层, objectType=article, longId=135837, objectId=7aa013583eb2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7aa013583eb2, replyNumber=0, likeNumber=87, createdTime=2018-04-21, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7aa013583eb2, moduleTitle=Blood：基于RNA的FLT3-ITD检测，可用于儿童急性髓系白血病患者的危险分层, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7aa013583eb2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538872, encodeId=0f0515388e234, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：在FLT3ITD急性髓系白血病中，FLT3酪氨酸激酶抑制剂处理可暴露谷氨酰胺水解的代谢依赖性, objectType=article, longId=130260, objectId=569b13026062, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=569b13026062, replyNumber=0, likeNumber=54, createdTime=2018-02-23, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=569b13026062, moduleTitle=Blood：在FLT3ITD急性髓系白血病中，FLT3酪氨酸激酶抑制剂处理可暴露谷氨酰胺水解的代谢依赖性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=569b13026062)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538871, encodeId=3d7115388e190, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：FF-10101，一种新型FLT3抑制剂，为携带FLT3突变的AML患者带来新的希望。, objectType=article, longId=122607, objectId=bd0012260ee7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bd0012260ee7, replyNumber=0, likeNumber=59, createdTime=2017-12-08, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bd0012260ee7, moduleTitle=Blood：FF-10101，一种新型FLT3抑制剂，为携带FLT3突变的AML患者带来新的希望。, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bd0012260ee7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538870, encodeId=80ce15388e03a, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Blood：突破，美国药监局通过用于治疗FLT3基因突变的急性骨髓性白血病的新药, objectType=article, longId=104077, objectId=19a81040e72a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19a81040e72a, replyNumber=0, likeNumber=56, createdTime=2017-07-01, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19a81040e72a, moduleTitle=Blood：突破，美国药监局通过用于治疗FLT3基因突变的急性骨髓性白血病的新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19a81040e72a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1538869, encodeId=6fa71538869d7, content=<a href='/topic/show?id=5f04e51467' target=_blank style='color:#2F92EE;'>#FLT3#</a>, objectTitle=Lancet Oncol：Gilteritinib可选择性抑制复发或难治性AML的FLT3突变, objectType=article, longId=103816, objectId=a3e41038167f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a3e41038167f, replyNumber=0, likeNumber=46, createdTime=2017-06-30, rootId=0, userName=fengyi816, userId=57a713069145, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a3e41038167f, moduleTitle=Lancet Oncol：Gilteritinib可选择性抑制复发或难治性AML的FLT3突变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a3e41038167f)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

FLT3

2020-05-29

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：靶向PRMT1介导的FLT3甲基化有望打破MLL重排型ALL的持续存在

2019-08-11

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：环状RNA，circMYBL2，可调节FLT2的表达促进FLT3-ITD AML进展

2019-08-10

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：PRMT1介导FLT3甲基化促进FLT3-ITD+AML细胞存活维持

2019-06-26

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：在急性髓系白血病中，NPM1c如何影响FLT3-D835Y的定位及信号？

2019-06-24

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

第24届EHA：pan-FLT3 / pan-BTK抑制剂CG-806的临床前数据

2019-06-18

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Lancet Oncol：采用quizartinib治疗复发性/难治性FLT3-ITD阳性的急性髓系白血病

2019-06-08

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：FLT3-ITD如何干扰急性早幼粒白血病治疗效果？

2019-02-10

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

J Med Chem:合肥研究院研发出针对急性髓性白血病FLT3-ITD突变选择性的第三代新型FLT3激酶抑制剂

2019-01-11

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：Midostaurin可明显延长携带FLT3-ITD的急性髓系白血病患者的无进展存活期

2019-01-10

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：竺晓凡/程涛教授团队取得重大突破，揭晓FLT3为PRC2突变T-ALL潜在治疗靶点！

2018-10-17

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Lancet Oncol：单药应用时，奎轧替尼能否为FLT3 ITD阳性复发难治AML带来获益？

2018-08-16

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Stem cells：Fms样酪氨酸激酶3-配体（Flt3-L）可促进CD8α+类浆细胞前体树突状细胞亚群的发展和功能

2018-08-04

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：Quizartinib单药治疗复发性/难治性FLT3-ITD突变型急性髓系白血病的效果和安全性

2018-06-09

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Lancet oncol：Quizartinib，FLT3抑制剂，单独用于复发性/难治性急性髓系白血病患者可获得良好疗效

2018-06-02

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：酪氨酸激酶抑制剂诱导的DNA修复缺陷使FLT3(ITD)阳性的白血病细胞对PARP1抑制剂治疗敏感

2018-05-24

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：基于RNA的FLT3-ITD检测，可用于儿童急性髓系白血病患者的危险分层

2018-04-21

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：在FLT3ITD急性髓系白血病中，FLT3酪氨酸激酶抑制剂处理可暴露谷氨酰胺水解的代谢依赖性

2018-02-23

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：FF-10101，一种新型FLT3抑制剂，为携带FLT3突变的AML患者带来新的希望。

2017-12-08

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Blood：突破，美国药监局通过用于治疗FLT3基因突变的急性骨髓性白血病的新药

2017-07-01

fengyi816 (审核中...)

前往app查看评论内容

#FLT3#

Lancet Oncol：Gilteritinib可选择性抑制复发或难治性AML的FLT3突变

2017-06-30

科室
- - 订阅+
  - 更多科室
工具
服务